NovoCure (NVCR) is an innovative medical device company that is developing the fourth modality in cancer treatment. I rate NovoCure a buy. As the lead and only developer of Tumor Treating Field (TTField), the company has the potential to gain a significant share of the vast cancer treatment market. Even though the valuation of NovoCure shares seems rich, I think the market does not fully appreciate the potential of this treatment modality. Hence, investing in NovoCure at current share price can produce multi-bagger returns in five to ten years. This article intends to